摘要
目的：比较重组人促红细胞生成素-β（rHuEPO-β）和重组人促红细胞生成素-α（rHuEPO-α）治疗肾性贫血的疗效和不良反应。方法选取2012年2月至2013年5月在枣庄市市中区人民医院维持性血液透析且血红蛋白（Hb）〈90 g/ L 的患者49例为研究对象，随机分为两组，分别应用 rHuEPO-β（实验组）和 rHuEPO-α（对照组）皮下注射治疗，观察比较两组治疗前后 Hb、红细胞压积变化、达到 Hb 目标值平均时间及促红细胞生成素（EPO）平均使用剂量，并观察不良反应的发生情况。结果两组治疗4周后 Hb 较治疗前明显升高（P 〈0.05）；治疗4、8、12周后，实验组 Hb 均较对照组高（P 〈0.05）；治疗16周后，两组 Hb 水平比较差异无统计学意义（P 〉0.05）。实验组患者 Hb 达到目标值平均使用天数及平均使用 EPO 剂量较对照组少（P 〈0.05）。实验组较对照组不良反应发生率低。结论皮下注射 rHuEPO-β和 rHuEPO-α治疗肾性贫血均有效，但 rHuEPO-β治疗肾性贫血较rHuEPO-α起效快，用量少，依从性好，不良反应少。
Objective To compare the curative effect and adverse reaction of recombinant hu-man erythropoietin beta（rHuEPO-β）and recombinant human erythropoietin alpha（ rHuEPO-α）in the treatment of renal anemia. Methods Forty-nine patients unterwent maintenance hemodialysis and hemo-globin（Hb） 〈 90 g / L from February 2012 to May 2013 in people’s hospital of Shizhong district of Zaozhuang were chose as the object of study,and were divided into two groups randomly. Experimental group was given rHuEPO-β with subcutaneous injection and control group was given rHuEPO-α with sub-cutaneous injection respectively. The hemoglobin,hematocrit changes,the average time to achieve Hb targets value,the average dose of erythropoietin（ EPO）using,and adverse reactions between the two groups before and after treatment was compared. Results Compared with before treatment,the levels of Hb in both groups increased significantly at 4 weeks after treatment（P 〈 0. 05）;the levels of Hb in ex-perimental group were higher than that in control group at 4,8,12 weeks after treatment（P 〈 0. 05）;af-ter 16 weeks of treatment,there was no significant difference in Hb levels between the two groups（P 〉0. 05）. The average time to achieve Hb targets value and the average dose of erythropoietin（EPO）using in the experimental group were lower than those in the control group（P 〈 0. 05）. The experimental group had less adverse reaction than that in the control group. Conclusions Subcutaneous injection of rHuE-PO-β and rHuEPO-α in treatment of renal anemia are effective,but rHuEPO-β has more rapid onset, less dosage,better compliance and less adverse reaction than rHuEPO-α in treatment of renal anemia.
出处
《中国实用医刊》
2014年第14期5-6,共2页
Chinese Journal of Practical Medicine
